We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 738

Removal of 'No-Objection-Certificate' brings relief to plant breeders
  • RNA IP Attorneys
  • India
  • August 9 2017

With the new amendment issued by Protection of plant varieties and farmers' rights authority (PPV&FR Authority), now the plant breeders will not be


Clinical trials lawyer welcomes FDA programme on Indian clinical trials
  • Leigh Day
  • India
  • July 14 2017

Clinical trials lawyer Gene Matthews has welcomed a push from the Federal Drug Agency (FDA) to promote safety and quality in clinical trials that are


Amendments to the legal metrology (packaged commodities) rules, 2011
  • Khaitan & Co
  • India
  • July 5 2017

The purpose of the Legal Metrology (Packaged Commodities) Rules, 2011 (PCR) is to regulate pre-packaged commodities. Under the PCR, pre-packaged


India: Bombay High Court holds that Feranta not deceptively similar to Intas Ferintas
  • SS Rana & Co
  • India
  • June 28 2017

In a recent case filed by Ajanta Pharma Ltd (hereinafter referred to as the "Plaintiff") before the Bombay High Court (hereinafter referred to as the


Lively Debate on Bolar Provisions at the Delhi High Court
  • RNA IP Attorneys
  • India
  • June 28 2017

Bolar Provision provided under Section 107 A of the Indian Patent Act was subject of next round of litigation between Natco and Bayer over Sorafenib


Business expenses of pharma companies - A regulatory hurdle
  • Lakshmikumaran & Sridharan
  • India
  • June 20 2017

Pharmaceutical companies incur huge expenses in launching and promoting their products by way of gifts to medical professionals, holding conferences


Cipla v Novartis: import qualifies as working of patent
  • LexOrbis
  • India
  • May 17 2017

The Indian pharmaceutical industry is a major manufacturer of cost-effective generic drugs and is set to become the leading exporter of generic


India: Trade dress and the importance of visual appearance
  • RNA IP Attorneys
  • India
  • May 1 2017

Marketers traditionally focus on designing advertising campaigns and other promotional strategies to promote a brand name. However, with evolving


Uncertainty remains over scope of value added products and biological resources
  • LexOrbis
  • India
  • April 26 2017

In recognition of India's rich biodiversity, the Biological Diversity Act 2002 is designed to help promote the sustainable use of its components, as


Monsanto Asserts no Government role in determining the Licensing Fee
  • RNA IP Attorneys
  • India
  • April 26 2017

The tug of war between Monsanto and its erstwhile licensees over licensing fee and Patent infringement continues unabated. The